Match!
Erik Lerkevang Grove
Aarhus University Hospital
202Publications
27H-index
2,696Citations
Publications 205
Newest
Source
Source
Source
Source
Venous thromboembolism (VTE) may affects all parts of the venous circulation, but frequently manifests as deep vein thrombosis or pulmonary embolism. Annually, around 10 million cases are diagnosed worldwide, and VTE constitutes a growing global health burden with increasing incidence and prevalence (1,2). VTE is associated with substantial morbidity and mortality, and about 30% of all patients with VTE experience a recurrent event within 10 years (3). Traditionally, vitamin K antagonists (VKA) ...
Source
#1Liv VernstrømH-Index: 1
#2Esben LaugesenH-Index: 11
Last.Kristian Løkke FunckH-Index: 4
view all 8 authors...
Source
#1Juhani KnuutiH-Index: 85
#2William WijnsH-Index: 102
Last.Brian ClappH-Index: 1
view all 130 authors...
6 CitationsSource
#1Maja Hellfritzsch (University of Southern Denmark)H-Index: 8
#2Kasper Adelborg (Aarhus University Hospital)H-Index: 10
Last.Erik Lerkevang Grove (AU: Aarhus University)H-Index: 27
view all 7 authors...
Source
#2Erik Lerkevang Grove (AU: Aarhus University)H-Index: 27
Last.Anne-Mette Hvas (AU: Aarhus University)H-Index: 8
view all 3 authors...
Primary prevention of cardiovascular events with aspirin remains controversial, as the risk of bleeding might outweigh the benefits. Recently, new evidence has emerged from the ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events), ASCEND (A Study of Cardiovascular Events in Diabetes), and ASPREE (Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly) trials. The aim of this study was to perform a systematic review and meta-analysis of aspirin's efficacy and safety ...
Source
12345678910